Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases
Inari Medical, now part of Stryker (NYSE: SYK), has launched the Artix™ Thrombectomy System, a new medical device designed for peripheral arterial thrombectomy. The system combines aspiration and mechanical thrombectomy capabilities to address arterial blood clots in the legs, which are life- and limb-threatening emergencies.
The Artix system features a dual mechanical thrombectomy and aspiration toolkit, capable of removing acute to chronic clots in a single session. It includes an 8 Fr. low-profile sheath available in 65cm and 90cm lengths, and an innovative over-the-wire mechanical element. The system also incorporates a covered nitinol mesh funnel to minimize clot migration risk.
The first commercial case using Artix was performed by Dr. Jonathan Bowman at Norwalk Hospital on October 19, 2024. The device aims to overcome limitations of existing therapies, which can lead to ineffective clot retrieval, significant blood loss, vessel trauma, and high rates of lytic use.
Inari Medical, ora parte di Stryker (NYSE: SYK), ha lanciato il Artix™ Thrombectomy System, un nuovo dispositivo medico progettato per la trombectomia arteriosa periferica. Il sistema combina capacità di aspirazione e trombectomia meccanica per affrontare i coaguli di sangue arteriosi nelle gambe, che rappresentano emergenze potenzialmente letali per la vita e gli arti.
Il sistema Artix presenta un kit duale di trombectomia meccanica e aspirazione, in grado di rimuovere coaguli acuti e cronici in una singola sessione. Include un manicotto a basso profilo da 8 Fr. disponibile in lunghezze di 65 cm e 90 cm, e un innovativo elemento meccanico over-the-wire. Il sistema incorpora anche un imbuto in rete di nitinol coperto per ridurre al minimo il rischio di migrazione del coagulo.
Il primo caso commerciale utilizzando Artix è stato eseguito dal Dr. Jonathan Bowman presso il Norwalk Hospital il 19 ottobre 2024. Il dispositivo mira a superare le limitazioni delle terapie esistenti, che possono portare a un recupero inefficace dei coaguli, a perdite di sangue significative, a traumi ai vasi e a elevate percentuali di utilizzo di lytic.
Inari Medical, ahora parte de Stryker (NYSE: SYK), ha lanzado el Sistema de Trombectomía Artix™, un nuevo dispositivo médico diseñado para la trombectomía arterial periférica. El sistema combina capacidades de aspiración y trombectomía mecánica para abordar los coágulos de sangre arteriales en las piernas, que son emergencias que amenazan la vida y la extremidad.
El sistema Artix cuenta con un kit dual de trombectomía mecánica y aspiración, capaz de eliminar coágulos agudos a crónicos en una sola sesión. Incluye una funda de bajo perfil de 8 Fr. disponible en longitudes de 65 cm y 90 cm, y un innovador elemento mecánico over-the-wire. El sistema también incorpora un embudo de malla de nitinol cubierto para minimizar el riesgo de migración del coágulo.
El primer caso comercial utilizando Artix fue realizado por el Dr. Jonathan Bowman en el Hospital Norwalk el 19 de octubre de 2024. El dispositivo tiene como objetivo superar las limitaciones de las terapias existentes, que pueden llevar a una recuperación ineficaz de los coágulos, a pérdidas significativas de sangre, a traumas en los vasos y a altas tasas de uso de líticos.
이나리 메디컬은 현재 스트라이커 (NYSE: SYK)의 일부로, 말초 동맥 색전 제거를 위해 설계된 새로운 의료 기기인 아르틱스™ 색전 제거 시스템을 출시했습니다. 이 시스템은 다리의 동맥 혈전 문제를 해결하기 위해 흡입 및 기계적 색전 제거 기능을 결합하여 생명과 사지를 위협하는 응급 상황에 대응합니다.
아르틱스 시스템은 급성에서 만성 혈전을 단일 세션으로 제거할 수 있는 이중 기계적 색전 제거 및 흡입 도구를 특징으로 합니다. 65cm 및 90cm 길이로 제공되는 8 Fr. 저프로파일 시스가 포함되어 있으며, 혁신적인 오버 더 와이어 기계 요소가 있습니다. 이 시스템은 또한 혈전의 이동 위험을 최소화하기 위해 덮인 니티놀 메쉬 깔때기를 통합하고 있습니다.
아르틱스를 사용한 첫 상업적 사례는 2024년 10월 19일 노워크 병원에서 조나단 보우먼 박사에 의해 수행되었습니다. 이 장치는 효과적이지 않은 혈전 제거, 상당한 출혈, 혈관 손상 및 높은 용해제 사용률로 이어질 수 있는 기존 치료의 한계를 극복하는 것을 목표로 합니다.
Inari Medical, désormais partie de Stryker (NYSE: SYK), a lancé le Système de Thrombectomie Artix™, un nouvel appareil médical conçu pour la thrombectomie artérielle périphérique. Le système combine des capacités d'aspiration et de thrombectomie mécanique pour traiter les caillots sanguins artériels dans les jambes, qui sont des urgences menaçant la vie et les membres.
Le système Artix comprend un kit dual de thrombectomie mécanique et d'aspiration, capable d'éliminer des caillots aigus à chroniques en une seule séance. Il inclut une gaine à profil bas de 8 Fr. disponible en longueurs de 65 cm et 90 cm, ainsi qu'un élément mécanique innovant over-the-wire. Le système intègre également un entonnoir en maille de nitinol recouvert pour minimiser le risque de migration du caillot.
Le premier cas commercial utilisant Artix a été réalisé par le Dr. Jonathan Bowman à l'hôpital de Norwalk le 19 octobre 2024. L'appareil vise à surmonter les limitations des thérapies existantes, qui peuvent conduire à une récupération inefficace des caillots, à des pertes sanguines significatives, à des traumatismes vasculaires et à des taux élevés d'utilisation de lytique.
Inari Medical, jetzt Teil von Stryker (NYSE: SYK), hat das Artix™ Thrombectomy System auf den Markt gebracht, ein neues medizinisches Gerät, das für die periphere arterielle Thrombektomie entwickelt wurde. Das System kombiniert Aspiration und mechanische Thrombektomie, um arterielle Blutgerinnsel in den Beinen zu behandeln, die lebensbedrohliche Notfälle darstellen.
Das Artix-System verfügt über ein duales Werkzeugset für mechanische Thrombektomie und Aspiration, das in der Lage ist, akute bis chronische Gerinnsel in einer einzigen Sitzung zu entfernen. Es umfasst eine 8 Fr. Low-Profile-Hülle, die in Längen von 65 cm und 90 cm erhältlich ist, sowie ein innovatives Over-the-Wire-Mechanismus. Das System enthält auch einen abgedeckten Nitinol-Mesh-Trichter, um das Risiko einer Gerinnselwanderung zu minimieren.
Der erste kommerzielle Fall mit Artix wurde am 19. Oktober 2024 von Dr. Jonathan Bowman im Norwalk Hospital durchgeführt. Das Gerät zielt darauf ab, die Einschränkungen bestehender Therapien zu überwinden, die zu ineffektiven Gerinnselentfernungen, erheblichen Blutverlusten, Gefäßverletzungen und hohen Raten von lytischen Anwendungen führen können.
- First-of-its-kind dual mechanical and aspiration thrombectomy system for arterial use
- Potential to replace open surgical repairs in many arterial cases
- Addresses limitations of existing therapies
- Expands treatment options for complex and distal interventions
- None.
Insights
Stryker's expansion of its thrombectomy portfolio through the newly acquired Inari Medical represents a strategic product diversification that could strengthen its competitive position in the interventional market. The Artix Thrombectomy System marks Inari's entry into the arterial thrombectomy space, complementing their established venous thrombectomy offerings and creating a more comprehensive vascular intervention portfolio for Stryker.
This launch addresses significant unmet needs in peripheral arterial thromboembolism treatment, targeting critical limitations of current therapies including ineffective clot retrieval, blood loss, and high complication rates. The system's dual-action capability (aspiration plus mechanical thrombectomy) provides physicians with procedural versatility that could potentially reduce the need for open surgical interventions or amputations.
From a market perspective, this launch strategically positions Stryker/Inari to capture market share in the growing peripheral vascular intervention segment, potentially reducing procedure costs by addressing complications that lead to additional procedures. The commercial launch timing (following the first case in October 2024) suggests Stryker is maintaining Inari's innovation pipeline post-acquisition, which should reassure investors about the integration process.
The product's differentiated features—particularly the 8 Fr low-profile design and over-the-wire mechanical element—provide meaningful clinical advantages that could drive physician adoption and preference, potentially accelerating revenue contribution from this new product line.
The Artix Thrombectomy System represents a significant clinical advancement in addressing the complexities of arterial thromboembolism. The dual-capability approach combining both aspiration and mechanical thrombectomy provides interventionalists with enhanced procedural control and versatility—critical factors when treating life- and limb-threatening conditions.
The system's design specifically addresses key clinical challenges including: 1) handling both acute and chronic clots in a single session, potentially reducing procedure time and improving outcomes; 2) minimizing embolization risk through the covered nitinol mesh funnel; and 3) maintaining vessel access throughout the procedure via the over-the-wire design.
The 8 Fr low-profile, kink-resistant sheaths (available in 65cm and 90cm lengths) enable access to more distal lesions, potentially expanding the treatable patient population and reducing the need for more invasive surgical approaches. Dr. Bowman's statement that Artix could replace open surgical repair in many arterial cases suggests this device could drive a shift toward less invasive treatment paradigms.
From a clinical outcomes perspective, reducing reliance on thrombolytics ("lytic use") is particularly valuable as it may decrease bleeding complications while potentially improving efficacy in chronic thrombus scenarios where lytics often underperform. The combined mechanical and aspiration approach appears well-suited to address the varying composition and chronicity of arterial thrombi encountered in clinical practice.
An arterial blood clot in the leg is a life- and limb-threatening emergency requiring immediate treatment. However, existing therapies for arterial thromboembolism can lead to:
- Ineffective clot retrieval leading to additional procedures (open surgery or amputation1,2)
- Significant blood loss1
- Adverse events such as arterial embolization and vessel trauma2,3
- High rates of lytic use, which may result in complications1,2
The Artix System builds on the success of Inari's venous thrombectomy devices and is its inaugural entry into the arterial space. Inari offers a comprehensive toolkit approach to arterial thrombectomy with an innovative, over-the-wire system that provides physicians with the flexibility to aspirate and/or mechanically extract a clot.
Jonathan Bowman, MD FACS, Chief of Vascular at Norwalk Hospital in
Key distinctive features of the Artix system include:
- Dual mechanical thrombectomy and aspiration toolkit designed to remove acute to chronic clots in a single session via a streamlined procedure4
- Aspiration-capable, 8 Fr. low profile, trackable, kink-resistant sheath in both 65cm and 90cm lengths expands treatment options by enabling more complex and distal interventions
- Innovative over-the-wire mechanical element designed to effectively collect and retrieve acute-to-chronic clot4
- Covered nitinol mesh funnel provides temporary flow restriction during the procedure to minimize the risk of arterial clot migration5
"There is a real clinical need to address chronic thrombi and decrease the risk of clot migration. Artix will raise the bar of effective arterial thrombectomy," said Tom Tu, MD, Chief Medical Officer of Inari Medical. "We are excited to bring Inari's core competency in thrombectomy to the arterial space with the goal of improving outcomes."
For more information, visit https://www.inarimedical.com/artix-system
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
On February 19, 2025, Stryker acquired Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.
Media contact:
Sherri Oakson
Senior Director, Communications
MedSurg and Neurotechnology
sherri.oakson@stryker.com
- De Donato et al. The INDIAN Trial. Eur J Vasc Endovasc Surg. 2021; 61: 820-828.
- Heller et al. Percutaneous Mechanical Thrombectomy Using Rotarex Device in Acute Limb Ischemia in Infrainguinal Occlusions. BioMed Research International. 2017.
- Olinic et al. Acute Limb Ischemia: An Update on Diagnosis and Management. J Clin Med. 2019.
- Designed to remove acute to chronic arterial clots. According to benchtop testing compared to control. Internal data on file. Narula et al. JACC 2018;72:2153-63
- According to benchtop testing compared to control. Internal data on file. NOTE: To attempt to minimize risk of arterial embolization of blood clots, use of a device that entraps clots may potentially be helpful, but this has not yet been demonstrated to be effective in the arterial system.
Dr. Jonathan Bowman is a paid consultant of Inari Medical. All views and opinions expressed here by Dr. Jonathan Bowman are his own and do not represent those of Inari Medical.
Indications for Use: The Artix thin-walled sheath is indicated for: (1) The non-surgical removal of emboli and thrombi from blood vessels. (2) Injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. (3) Use as a conduit for endovascular devices. (4) Use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel. The funnel provides temporary vascular occlusion during these and other angiographic procedures. The Artix thin-walled sheath is intended for use in the peripheral vasculature. The Artix MT thrombectomy device is indicated for (1) the non-surgical removal of emboli and thrombi from a blood vessel; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix MT thrombectomy device is intended for use in the peripheral vasculature. The Artix AX aspiration catheter is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix AX aspiration catheter is intended for use in the peripheral vasculature. The FlowSaver blood return system is used with Inari Medical catheters and sheaths for autologous blood transfusion.
Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of these products.
View original content to download multimedia:https://www.prnewswire.com/news-releases/inari-medical-now-part-of-stryker-launches-artix-thrombectomy-system-designed-to-address-a-broad-spectrum-of-arterial-thrombus-cases-302394987.html
SOURCE Stryker
FAQ
What is the Artix Thrombectomy System launched by Stryker (SYK)?
When was the first commercial case of Stryker's (SYK) Artix system performed?
What are the key features of Stryker's (SYK) new Artix Thrombectomy System?
How does the Artix system improve upon existing arterial thrombectomy treatments for SYK?
What clinical advantages does Stryker's (SYK) Artix system offer for arterial procedures?
